Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
October 01, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
Immune Checkpoint Inhibitors Market to hit USD 189.1 billion by 2032, says Global Market Insights Inc.
October 01, 2024 05:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Immune Checkpoint Inhibitors Market size reached USD 47.4 billion in 2023 and is projected to register a CAGR of 16.7% from 2024 to 2032...
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
September 30, 2024 08:00 ET
|
Ichnos Glenmark Innovation
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase
September 27, 2024 08:33 ET
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it...
Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease
September 27, 2024 08:21 ET
|
Janssen Cilag International NV
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies1 BEERSE, BELGIUM, Sept. 27, 2024 (GLOBE NEWSWIRE) --...
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
September 27, 2024 08:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM will...
Orphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
September 26, 2024 07:14 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The orphan drugs market (희귀의약품 시장) was worth US$ 195.0 billion in 2023. The market is...
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
September 26, 2024 07:00 ET
|
Mural Oncology, Inc.
Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...
EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy
September 26, 2024 07:00 ET
|
EnnoDC
PRESS RELEASE EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy Versatile new technology featuring an...